Drug intelligence / Profile preview

ATH-391

Development stage: Preclinical
Lead developer: Athos Therapeutics
Modality: Small Molecules

Overview

ATH-391 is an investigational small molecule drug being developed by Athos Therapeutics. It is currently in the discovery or preclinical stage and is being explored as a potential therapy for acute myeloid leukemia (AML). The specific mechanism of action, molecular target, and detailed pharmacological profile have not been publicly disclosed. Athos Therapeutics focuses on precision therapeutics for autoimmune diseases and cancer using AI-based drug discovery platforms[1][4].

Beyond the preview

Go deeper on ATH-391.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATH-391.

Explore the full profile